-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Nafamostat
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/81525-10-2.gif)
| Category | SARS-CoV |
| CAS | 81525-10-2 |
| Description | Nafamostat is a broad spectrum serine protease inhibitor and kallikrein inhibitor. It inhibits blood coagulation and used as an anticoagulant. It is also a possible complement inhibitor. It is mainly used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. It is formulated with HCl salt due to its basic tendencies. |
Product Information
| Synonyms | FUT-175; FUT 175; FUT175; 6-Amidino-2-naphthyl 4-guanidinobenzoate;(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;Benzoic acid,4-[(aminoiminomethyl)amino]-, 6-(aminoiminomethyl)-2-naphthalenyl ester |
| IUPAC Name | (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate |
| Molecular Weight | 347.37 |
| Molecular Formula | C19H17N5O2 |
| Canonical SMILES | C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N |
| InChI | InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24) |
| InChIKey | MQQNFDZXWVTQEH-UHFFFAOYSA-N |
| Boiling Point | 586.0±60.0 °C | Condition: Press: 760 Torr |
| Melting Point | serine protease inhibitor and kallikrein inhibitor |
| Flash Point | 339.1±34.3 °C |
| Purity | 95% |
| Density | 1.39±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Application | Nafamostat inhibits blood coagulation and used as an anticoagulant. It is also a possible complement inhibitor. It is mainly used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. |
| Shelf Life | 2 month in rt, long time |
| Storage | -20°C Freezer |
| Complexity | 552 |
| Exact Mass | 347.13822480 |
| Index Of Refraction | 1.694 |
| In Vitro | Tranilast (FUT-175) is an antiallergic drug for bronchial asthma. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. It has also been investigated for use as an antiproliferative drug on drug-eluting stents.A 20-40 mg/h dose of FUT-175 prolonged coagulation time sufficiently in the instrumental blood of the extracorporeal circuit but not in the systemic blood. Its anticoagulant activity decreased immediately after hemodialysis. Therefore, we could manage all patients without any bleeding trouble during hemodialysis with FUT-175 as an anticoagulant. Although there were side effects of FUT-175, such as nausea, vomiting, itching and eruption, they were not serious, and FUT-175 could be administered without interruption. FUT-175 seems to be useful as an anticoagulant during hemodialysis for patients susceptible to bleeding. |
| PSA | 138.07000 |
| Target | Ser/Thr Protease; Apoptosis; SARS-CoV |
| Vapor Pressure | 0.0±1.9 mmHg at 25°C |
| XLogP3-AA | 2 |
